Commercial Drugmakers & Vaccine Developers

Own companies whose core businesses turn proprietary medicines and vaccines into commercial revenue, rather than businesses dependent on AI infrastructure spending. With technology sentiment unsettled, this basket shifts exposure toward treatment demand and company-specific clinical and commercial execution. Diversification across therapeutic areas limits reliance on any single drug franchise, although patent expirations, pricing pressure and trial failures remain material risks. Launch basket (equal weight): ABBV, AMGN, MRK, LLY, JNJ, MRNA, GILD, VRTX Rules: 1. No inverse, leveraged or volatility ETFs. 2. Only names tradable at the enrolled brokers (Moomoo): no OTC listings, no dead tickers, nothing on the refused list.